

A 3D rendering of several tumor spheroids of varying sizes, colored in shades of red and pink, set against a teal and orange gradient background. The spheroids have a textured, porous appearance.

MuScreen™

Syngeneic and tumor homograft
in vivo immunotherapy screening



A JSR Life Sciences Company

QUICKFACT

V1.0

Rapidly progress your immuno-oncology drug development programs with our highly experienced screening platform.

Choose **MuScreen** to:

- Screen agents using well-characterized syngeneic and tumor homograft models, with ICI benchmarking, baseline tumor immune profile, and tumor RNAseq data available
- Evaluate single or combination agent strategies
- Efficiently identify responder models
- Uncover mechanism of action and predictive biomarkers
- Benefit from Crown Bioscience covering the cost of the vehicle group for all models
- Maximize the value your MuScreen by choosing either FACS or Mouse I/O RNA-Seq Panel as an optional readout to fast-track *in vivo* preclinical immunotherapy development

Syngeneic Model Panels



Choose our well-characterized syngeneic model panels, displaying heterogeneous immune phenotypes, for rapid and large scale compound efficacy or PD evaluation.

Tumor Homograft Panel

Choose our unique tumor homograft models featuring clinically relevant mutations, for single agent immunotherapy and combination I/O and targeted agent efficacy assessment.

Our unique **MuPrime™** tumor homografts are transplants of spontaneous or carcinogen-induced GEMM tumors in immunocompetent syngeneic hosts:

- Carrying disease-relevant oncogenic mutations of human cancers including KRAS, PTEN, and TP53
- Preserving original GEMM tumor histo- and molecular pathology



Select the Models and Study Design To Suit Your Program

Get in touch



Sales

US: +1 858 622 2900
UK: +44 870 166 6234

busdev@crownbio.com
www.crownbio.com



Science

consultation@crownbio.com

